Allergic Rhinitis News and Research

RSS

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen.

30 Jan 2015

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

$Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis$

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis.

18 Dec 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Exposure to indoor air pollution affects children's lungs

Children with asthma and hay fever often struggle with their breathing. Add secondhand smoke, kerosene and biomass fuel to the mix and allergy and asthma symptoms increase.

7 Nov 2014

Children infected with enterovirus more likely to have type 1 diabetes

A new study published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that children who have been infected with enterovirus are 48% more likely to have developed type 1 diabetes. The study is by Dr Tsai Chung-Li, China Medical University, Taiwan, and colleagues.

20 Oct 2014

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.

25 Jul 2014

Reforestation can reduce ragweed pollen that triggers hay fever

When it comes to controlling hay fever-triggering ragweed plants on Detroit vacant lots, occasional mowing is worse than no mowing at all, and promoting reforestation might be the best solution.

18 Jun 2014

AeraMax air purifiers reduce exposure to allergens

The true scale of the allergy epidemic is revealed in the British Airborne Allergy Report commissioned by air purification specialists Fellowes, in association with national charity Allergy UK.

11 Jun 2014

Knowing summer allergies

As if a runny nose and red eyes weren't enough to ruin your warm weather look, summer allergies can gift you with even more than you've bargained for this year. In fact, some unusual symptoms can leave you looking like you lost a round in a boxing ring.

11 Jun 2014

Researchers identify target molecules for development of new allergy drugs

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital.

13 May 2014

Researchers identify several target molecules suitable for development of new allergy drugs

13 May 2014

Scientists shed light on runny nose

Scientists at the University of Colorado School of Medicine have shed light on one of the most common of ailments - the runny nose.

11 Apr 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

FDA approves ORALAIR sublingual allergy immunotherapy tablet

GREER Laboratories, Inc., a leading developer and provider of allergy immunotherapy products and services, today announced that the U.S. Food and Drug Administration has approved ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.

2 Apr 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

A small filter the size of a contact lens could possibly make life easier for some of the estimated 500 million people worldwide who suffer from itching, sneezing and a runny nose as soon as the pollen season starts.

10 Mar 2014

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.

5 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014